Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Foghorn Therapeutics Inc. FHTX

Healthcare Biotechnology
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact... see more

Recent & Breaking News (NDAQ:FHTX)

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewswire November 12, 2024

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

GlobeNewswire November 4, 2024

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

PR Newswire October 23, 2024

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

GlobeNewswire October 10, 2024

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

PR Newswire October 3, 2024

Foghorn Therapeutics to Participate in the BMO Oncology Summit

GlobeNewswire October 1, 2024

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

GlobeNewswire September 3, 2024

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

GlobeNewswire August 28, 2024

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

GlobeNewswire August 8, 2024

Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner

PR Newswire August 6, 2024

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

GlobeNewswire May 28, 2024

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

GlobeNewswire May 22, 2024

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire May 20, 2024

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

GlobeNewswire May 6, 2024

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

GlobeNewswire April 16, 2024

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

GlobeNewswire April 9, 2024

Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference

GlobeNewswire April 5, 2024

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

GlobeNewswire March 26, 2024

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

GlobeNewswire March 7, 2024

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

GlobeNewswire March 5, 2024